Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Fallers
Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower
Share Market News
ASX 200 jumps 2.6%, big 4 banks surge
Share Gainers
Why the Mesoblast (ASX:MSB) share price jumped 14% higher today
Share Fallers
These were the worst performing shares on the ASX 200 last week
Share Market News
ASX 200 drops, Trump has COVID-19, Mesoblast (ASX:MSB) share price sinks
Share Fallers
Why Beach, Fortescue, Mesoblast, & SeaLink shares are tumbling lower
Share Market News
ASX 200 down 0.95%: Mesoblast crashes lower on FDA update, Afterpay surges higher
Share Market News
Mesoblast (ASX:MSB) share price tumbles 32% lower on update
Share Market News
5 things to watch on the ASX 200 on Friday
Share Market News
Why the Mesoblast (ASX:MSB) share price is in a trading halt
Share Market News
ASX 200 up 1.6%: CBA higher on COVID-19 loan deferrals update, Reliance rockets
Share Market News
5 things to watch on the ASX 200 on Thursday
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
